Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Institute Of Medicine On 510(k) Review Program: Dump It

This article was originally published in The Gray Sheet

Executive Summary

The Institute of Medicine committee charged with reviewing FDA's 510(k) device pre-market review program is urging the agency to ditch the 35-year-old program and start fresh.

You may also be interested in...



Medtech-Supporter Sen. Al Franken To Resign, After Harassment Charges

Sen. Al Franken, D-Minn., who has championed key device regulatory reform changes favoring the medtech industry that are now law, will step down from his post, following newly revealed charges of sexual harassment by a former congressional staffer in 2006.

Scrutinizing Substantial Equivalence: 510(k) Predicate Standard Questioned At FDLI

Consultant and Food & Drug Law Institute Chair Sheila Hemeon-Heyer said it is time to remove the substantial equivalence mandate from the 510(k) program at the FDLI annual conference April 20. “The Gray Sheet” spoke to Hemeon-Heyer and CDRH Director Jeffrey Shuren about the idea.

People Briefs: IOM President, Edwards Lifesciences, Quest Diagnostics, Advanced ICU Care

Newly appointed IOM president is a Duke chancellor and Medtronic board member. Quest Diagnostics makes executive suite changes. Telemedicine firm Advanced ICU Care names chairman and CEO. More people briefs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel